Form 4: Cogent Bio Legal Chief Sells $2.5M in Stock

Cogent Biosciences' Chief Legal Officer, Evan Kearns, sold 65,000 shares of common stock for approximately $2.5 million under a pre-arranged trading plan.

Summary

• Evan Kearns, Chief Legal Officer of Cogent Biosciences, Inc. (COGT), disposed of 65,000 shares of common stock.
• The transaction occurred on December 26, 2025, at a weighted average price of $38.7 per share.
• The shares were sold in multiple transactions with prices ranging from $38.52 to $38.94.
• The total value of the shares sold is approximately $2,515,500 (65,000 shares * $38.7/share).
• Following this transaction, Evan Kearns beneficially owns 109,398 shares of common stock, which includes previously reported restricted stock units subject to vesting conditions.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can be seen as a slight negative, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns that it's a reaction to negative company-specific news. It's likely for personal financial planning.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not a reaction to recent company performance or news, which can mitigate negative market perception of insider selling.

Negatives

• An insider sale, even if pre-planned, reduces the direct equity stake of a key executive in the company, which can sometimes be perceived as a lack of confidence by some investors.

Risks

• No specific risks were mentioned in the filing beyond the general implications of an insider stock sale.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is specific to Cogent Biosciences and its Chief Legal Officer. Without broader context of insider activity across the biotechnology industry or within Cogent Biosciences, it is difficult to draw industry-wide conclusions. However, pre-planned sales via 10b5-1 plans are common across industries for executive liquidity and diversification.

Related Party Transactions

• Evan Kearns, Chief Legal Officer, is considered a related party, and his sale of company stock is a related party transaction.

Stakeholder Impact

• Shareholders may interpret the insider sale differently; some might view it as a neutral event due to the 10b5-1 plan, while others might see it as a slight negative signal regarding management's conviction in the stock's future appreciation.

Key Dates

Recommendation

The insider sale by the Chief Legal Officer, while notable, was conducted under a pre-arranged 10b5-1 plan. This suggests the sale was for personal financial planning rather than a reaction to new, undisclosed negative information. A single, pre-planned insider sale typically does not warrant a change in investment recommendation unless it's part of a larger pattern of insider selling or represents a significant portion of the insider's holdings, which is not explicitly detailed as such here. Therefore, a 'hold' recommendation is appropriate, pending further company-specific or industry-wide developments.

Keywords

Cogent Biosciences, COGT, Evan Kearns, Insider Sale, Form 4, Stock Transaction, Chief Legal Officer, 10b5-1 Plan